ALLOGENE THERAPEUTICS INC. - COMMON STOCK

Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 16:05:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology

09 Dec 2023 12:00:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in December Investor Conference

01 Dec 2023 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual Meeting

03 Nov 2023 12:00:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting

03 Nov 2023 12:00:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update

02 Nov 2023 16:02:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology

02 Nov 2023 09:00:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in November Investor Conferences

30 Oct 2023 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023

26 Oct 2023 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer

16 Oct 2023 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

27 Sep 2023 09:09:21 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in September Investor Conference

05 Sep 2023 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Appoints Earl Douglas as General Counsel

14 Aug 2023 08:30:38 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update

02 Aug 2023 16:02:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023

26 Jul 2023 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano

15 Jun 2023 09:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Departure of Chief Financial Officer

14 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano

09 Jun 2023 18:25:18 By Nasdaq GlobeNewswire

Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting

03 Jun 2023 09:00:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences

24 May 2023 08:30:00 By Nasdaq GlobeNewswire